Floatz logo

Dendritic Cell Tumor Fusion

Vaccines

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Vaccines cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Dendritic Cell Tumor Fusion is also rated in:

Primary Peritoneal CancerDormant
CCC
Indicative ·
51 / 100
View asset →
Fallopian Tube CancerDormant
CCC
Indicative ·
48 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →